Compare WEN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | OCS |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 3 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2000 | N/A |
| Metric | WEN | OCS |
|---|---|---|
| Price | $6.80 | $27.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 22 | 6 |
| Target Price | $8.88 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 7.2M | 190.5K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $2,176,891,000.00 | N/A |
| Revenue This Year | $2.35 | $466.06 |
| Revenue Next Year | $0.94 | $479.73 |
| P/E Ratio | $7.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.63 | $16.00 |
| 52 Week High | $13.06 | $30.68 |
| Indicator | WEN | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 56.96 |
| Support Level | $6.73 | $19.00 |
| Resistance Level | $7.34 | $27.93 |
| Average True Range (ATR) | 0.25 | 1.05 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 22.95 | 78.64 |
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.